华东医药：子公司产品被纳入国家医保及商保创新药目录

Core Viewpoint - The announcement by Huadong Medicine indicates changes in the management of its products under the new national medical insurance directory, which may impact the company's revenue and market positioning [1] Group 1: Product Adjustments - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., has had its Ustinumab injection liquid adjusted to regular directory management, with changes in the payment scope compared to the previous version of the drug directory [1] - The company's cooperative products, Senapali capsules and Pentanedioic acid linaclotide capsules, have been included in the negotiated drug section within the agreement period [1] - The drug Zewokaiolun injection liquid has been included in the commercial insurance innovative drug directory [1] Group 2: Other Products - Other products from the subsidiary that are already included in the national medical insurance directory have not experienced any changes in their directory status during this update [1]